Ceapro Reports Second Quarter 2011 Financial Results

Ceapro Reports Second Quarter 2011 Financial Results

ID: 44476

(firmenpresse) - EDMONTON, ALBERTA -- (Marketwire) -- 08/10/11 -- Ceapro Inc. (TSX VENTURE: CZO)("Ceapro" or the Company") today announced its financial results as at and for the three-month and the six-month periods ended June 30, 2011. These results are presented in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standards Board (IASB).

SECOND QUARTER 2011 HIGHLIGHTS

SUBSEQUENT TO QUARTER END

"The second quarter of 2011 represents another excellent quarter for Ceapro showing continued profitability and improvement in our balance sheet" said Gilles Gagnon, Acting CEO." These solid results were obtained through improved efficiencies by our highly qualified team and the strong support from our partners and particularly from our major customers who clearly recognize our capacity to develop and sell innovative products and technologies. We now look forward increasing our sales and expanding our pipeline through increased investments in R&D activities along with existing and new upcoming partners in 2011" he added.

FINANCIAL RESULTS FOR THE SECOND QUARTER AND THE FIRST SIX MONTHS ENDED JUNE 30, 2011

The complete audited annual report and financial statements are available for review on SEDAR at and on the Company's website at .

About Ceapro Inc.

Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit .

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Branko Jankovic
Vice President and CFO
Ceapro Inc.
(Edmonton): 780.917.8376





Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Paladin Labs Announces Premium Offer to Acquire Afexa Life Sciences for $0.55 per Share Marina Biotech Demonstrates In Vivo Knockdown of a microRNA With a CRN-Modified Antagomir
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 10.08.2011 - 12:00 Uhr
Sprache: Deutsch
News-ID 44476
Anzahl Zeichen: 0

contact information:
Town:

EDMONTON, ALBERTA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 235 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ceapro Reports Second Quarter 2011 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von

Ceapro Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ceapro Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z